Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
About this item
Full title
Author / Creator
He, Yundong , Peng, Shihong , Wang, Jinhua , Chen, Huang , Cong, Xiaonan , Chen, Ang , Hu, Meichun , Qin, Min , Wu, Haigang , Gao, Shuman , Wang, Liguo , Wang, Xin , Yi, Zhengfang and Liu, Mingyao
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Androgen receptor (AR) antagonist MDV3100 is the first therapeutic approach in treating castration-resistant prostate cancer (CRPC), but tumours frequently become drug resistant via multiple mechanisms including AR amplification and mutation. Here we identify the small molecule Ailanthone (AIL) as a potent inhibitor of both full-length AR (AR-FL) a...
Alternative Titles
Full title
Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_397854b72c3a42d8b708521339c3ef2d
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_397854b72c3a42d8b708521339c3ef2d
Other Identifiers
ISSN
2041-1723
E-ISSN
2041-1723
DOI
10.1038/ncomms13122
